Anti-Infective & Antiparasitic

Ivermectin Capsules — 12 mg

A 12 mg ivermectin capsule strength for diagnosis-specific antiparasitic care.

Evidence brief in review

lennoxRXProduct image pending

Common goals: Ingredient-level evidence supports ivermectin for selected parasitic infections.
Best program fit: Fits only a licensed-clinician pathway tied to supported parasitic indications, exposure history, body weight, interactions, and follow-up.
Format: Capsule · 12 mg

Partner education guide

Where this may fit in an offering.

Ingredient-level evidence supports ivermectin for selected parasitic infections. A 12 mg capsule can provide a defined unit strength when it matches the prescription. May support an infectious-disease or travel-medicine pathway with laboratory and exposure review.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Ingredient-level evidence supports ivermectin for selected parasitic infections.
A 12 mg capsule can provide a defined unit strength when it matches the prescription.
Diagnosis-specific follow-up can confirm whether treatment worked.

Program value

How it may support a program

May support an infectious-disease or travel-medicine pathway with laboratory and exposure review.
Creates a clear point for medication-interaction and Loa loa risk screening.

Ivermectin should not be presented for viral illness, cancer, or general wellness. A 12 mg capsule is not a universal dose and may differ from approved tablets.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Capsule · 12 mg. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration: Some supported uses involve a short course with organism-specific follow-up; onchocerciasis may require later reassessment. Do not generalize one schedule to another infection.
04Practical considerations: May support an infectious-disease or travel-medicine pathway with laboratory and exposure review.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May support an infectious-disease or travel-medicine pathway with laboratory and exposure review.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Dizziness, sleepiness, nausea, diarrhea, abdominal discomfort, itching, rash, or fatigue can occur.
Reactions may also reflect the parasite being treated; the pattern differs between strongyloidiasis and onchocerciasis.

Serious or important

Rare neurotoxicity can include confusion, altered consciousness, seizures, coma, or death. Severe reactions are a concern with heavy Loa loa infection.
Severe rash, low blood pressure, liver-test abnormalities, serious allergic reaction, or worsening neurologic symptoms requires urgent assessment.

Avoid or use only with specialist input

Use without a supported diagnosis, veterinary products, self-treatment for viral illness, cancer, or general wellness, or an unverified compounded source.
Known hypersensitivity, suspected heavy Loa loa exposure without appropriate evaluation, pregnancy or breastfeeding without a risk-benefit review, or use in a child under 15 kg without specialist guidance.

Screening checklist

Confirm the suspected or proven parasite, travel and residence history, body weight, Loa loa exposure risk, pregnancy and breastfeeding status, liver and neurologic history, immune suppression, and all medicines including warfarin.
Verify the exact capsule strength and determine whether diagnostic testing and follow-up testing are needed for the organism.

When to refer

Altered mental status, seizure, severe weakness, breathing difficulty, syncope, severe rash, or signs of disseminated infection requires urgent medical care.
Possible Loa loa exposure, disseminated strongyloidiasis, major immune suppression, pregnancy, very low body weight, uncertain diagnosis, or treatment failure warrants specialist input.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Ivermectin has established diagnosis-specific antiparasitic uses; a 12 mg capsule strength is not a universal regimen.

01 / Human research

The clearest clinical signal

DailyMed and CDC sources support weight- and organism-specific ivermectin use for selected parasitic infections such as strongyloidiasis and onchocerciasis.

02 / Real-world reports

What people describe

People may value a defined capsule strength, but diagnosis, body weight, exposure history, Loa loa risk, interactions, and follow-up determine whether it fits.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Neurotoxicity, severe Loa loa reactions, pregnancy and pediatric considerations, liver or neurologic history, and product-source quality require review.

Does the research match this exact product?

Partly. Ingredient-level evidence does not automatically establish a compounded 12 mg capsule or any unsupported indication.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments